Sartorius AG

euro adhoc: Sartorius AG
Nine-month earnings for 2004 already above full-year earnings for 2003
Group sales revenue and order intake significantly up from the previous yearÂ’s level
Debt further reduced
Full-year targets unchanged

---------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. ---------------------------------------------------------------------

In the first nine-month period of 2004, the Sartorius Group increased its sales revenue by 3.9% (currency-adjusted: 6.6%) to €337.5 million from €324.8 million a year ago. We raised sales revenue of the Biotechnology Division by 2.9% (currency-adjusted:  5.7%) to €170.8 million (previous year:  Â€166.1 million), and that of the Mechatronics Division by 5.0% (currency-adjusted: 7.4%) to €166.6 million (previous year: €158.7 million).

Concerning order intake, we posted a substantial increase of 9.1% (currency-adjusted: 12.3%) to €347.6 million (previous year:  Â€318.6 million). For the Biotechnology Division, order intake rose 10.1% (currency-adjusted: 13.8%); for the Mechatronics Division, order intake climbed 8.1% (currency-adjusted: 10.7%). We boosted EBITDA in the first nine-month period of 2004 to €36.6 million from €16.6 million a year ago and improved EBIT to €20.3 million (previous year:  - €0.7 million). We raised EBIT for the Biotechnology Division to €10.2 million (previous year:  Â€0.7 million); and increased that for the Mechatronics Division to €10.1 million (previous year: - €1.5 million).

We primarily used net cash flow of €21.8 million (previous year: €26.6 million) to reduce our net debt to €92.1 million (reporting date on December 31, 2003: €105.0 million).

We continue to adhere to our full-year targets for increasing sales revenue in the mid- to upper percentage range of one digit and for doubling EBIT.

end of announcement                                euro adhoc 28.10.2004 08:00:00

Further inquiry note: Heiko Imöhl Vice President Treasury & Investor Relations phone : +49 551 308 4034

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    Prime Standard, CDAX, Prime All Share, Technologie All Share
Börsen:  Berliner Wertpapierbörse / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-WĂĽrttembergische Wertpapierbörse / free trade
              Börse DĂĽsseldorf / free trade
              Bayerische Börse / free trade
              Bremer Wertpapierbörse (BWB) / free trade
              Frankfurter Wertpapierbörse / official dealing
              Niedersächsische Börse zu Hannover / official dealing

Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: